AstraZeneca is Using Technology to Create Sustainable Inhalers

Published on: 07 October 2022
tinywow Honeywell-Begins-Production-Of-Near-Zero-Global-Warming-Potential-Medical-Propellant-1024x512 6425987

AstraZeneca, a company that specialises in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), is working to incorporate Honeywell’s Solstice Air technology, which is being evaluated for use as a medical propellant and has up to 99.9% less GWP than propellants currently used in inhaled respiratory medicines.

This non-flammable, near-zero GWP, non-ozone-depleting, volatile organic compound propellant is in clinical development today for pressurised metered-dose inhalers (pMDIs). Solstice Air, a near-zero global-warming-potential (GWP) medical propellant for use in respiratory inhalers and developed by Honeywell, will be manufactured in a plant in Baton Rouge, Louisiana.

Today’s healthcare organisations face a rapidly accelerating suite of climate and ESG-related challenges, including rising energy costs, physical disruptions, and a list of ever-increasing expectations from investors and regulators as well as doctors, patients, and communities.

Until recently, ESG and sustainability topics felt secondary to the core missions of patient care and organisational survival, but it’s become increasingly clear that these topics are intimately linked to the success of those core missions.

The healthcare industry is a major source of carbon emissions, and recent research by The World Bank and Health Care Without Harm estimates the sector’s emissions at over 2 gigatons or roughly 4% to 5% of the world’s total. In turn, these emissions can be important social determinants of health, aggravating respiratory and cardiovascular disease, causing injuries from natural and weather-related disasters, altering the distribution of food resources, and changing patterns in illness and infectious diseases.

Honeywell has invested more than $1 billion in research, development and new capacity for its Solstice technology, having anticipated the need for lower-GWP solutions to combat climate change more than a decade ago. The Solstice product line, which helps customers lower their greenhouse gas emissions and improve energy efficiency without sacrificing end-product performance, includes refrigerants for supermarkets, air conditioning for cars and trucks, blowing agents for insulation, propellants for personal and household care, and solvents for cleaning solutions.

Source: Environmental Leader

For more technological news

Share:
esg
esg
esg
esg
More from AstraZeneca PLC
Progress toward Zero Carbon: Accelerated delivery of our renewable energy sourcing targets
Progress toward Zero Carbon: Accelerated delivery of our renewable energy sourcing targets
Accelerating restoration of forests and biodiversity
Accelerating restoration of forests and biodiversity
With Honeywell, AstraZeneca advances the Ambition Zero Carbon program to create the next-generation of respiratory inhalers
With Honeywell, AstraZeneca advances the Ambition Zero Carbon program to create the next-generation of respiratory inhalers
New UK collaborations drive emission reductions while also restoring forests and biodiversity
New UK collaborations drive emission reductions while also restoring forests and biodiversity